When I saw the title of the webcasts, I crossed my fingers that Apabetalone would show synergy with SGLT2 inhibitors.

Why?

Well, this class of medications is the current wonder drug in medicine. They have quickly vaulted to the forefront of treatment either ahead or just behind Metformin in guidelines.

Prescriptions for these medications will be climbing for the next decade at least.

So, any future study involving Apabetalone and diabetics will see a significantly higher percentage of patients on SGLT2 inhibitors at baseline. Given the current findings, this should help Apabetalone achieve endpoints.

The CKD numbers were impressive. Some wanted to know GFR data but preventing MACE is more important. RVX should be able to get breakthrough status for MACE prevention in CKD imho.

As for the share price, many fatigued investors and traders are exiting. I can understand that. The financial picture remains unclear.

However, we know that a PAH and HIV study will be/are occurring. We also know that partnering discussions are happening on multiple fronts. This company is moving forward.

Ultimately, I would like to see many trials initiated with more than one partner if possible.

Patience should win out here in the end.

bfw